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Abstract
The recently shown association between apolipoprotein
E (APOE) genotype and depressive illness has been chal-
lenged by subsequent studies. However, controversial
results may derive from the different diagnostic criteria
used for depression and from the small numbers of
depressed patients included in the studies. We examined
the association between depression and the genetic
polymorphism of APOE in a large sample of depressed
patients, Alzheimer’s disease (AD) patients, and healthy
controls following clear definitions for late-life depres-
sion. The cumulative incidence of depression depending
on the age at onset of the first episode was examined by
survival analysis. Our data do not disconfirm the hypoth-
esis of depression sharing some common pathophysio-
logic features with AD, however, it seems very unlikely
that the APOE genotype will elucidate the assumed com-
mon mechanisms.
Introduction
The finding that the frequency of the apolipoprotein E
Â4 (APOE Â4) allele is increased in Alzheimer’s disease
(AD) [1] has led to numerous studies examining the allelic
distribution of APOE Â4 in other disorders, which share
common clinical and, presumably, aetiological character-
istics with AD. Depression is often accompanied by cog-
nitive deficits similar to those occurring in AD [2] and has
been discussed as a possible risk factor for developing AD
[3]. Moreover, there seems to be a significant comorbidity
between depression and AD [4]. The increased frequency
of the APOE Â3/Â4 genotype in non-demented, late-onset
depressed patients [5] gave rise to the hypothesis that late-
onset depression (LOD) shares at least some common
pathophysiological mechanisms with AD. The observa-
tion that LOD is a risk factor for developing AD [6] and
that patients with AD and the APOE Â3/Â4 genotype show
increased depressive manifestations [7] seemed to
strengthen this hypothesis. However, other studies failed
to replicate a significant association between depression
and the genetic polymorphism of APOE [8–14] or showed
increased APOE Â4 allele frequency in a small subgroup of
elderly depressed patients with psychotic symptoms [15].
It is hitherto difficult to draw a final conclusion from the
results of these studies, because they only allow limited
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Table 1. APOE genotype and APOE Â4
allele distribution in healthy controls,
patients with EOD, patients with LOD and
AD patients
Healthy controls
(n = 191)
EOD patients
(n = 129)
LOD patients
(n = 31)
AD patients
(n = 102)
Â3Â3 109 (57.1%) 70 (54.3%) 18 (58.1%) 31 (30.4%)
Â2Â3 33 (17.3%) 20 (15.5%) 5 (16.1%) 9 (8.9%)
Â3Â4 46 (24.1%) 30 (23.3%) 7 (22.6%) 40 (39.2%)
Â4Â4 1 (0.5%) 6 (4.6%) – 19 (18.6%)
Â2Â4 2 (1.0%) 3 (2.3%) 1 (3.2%) 3 (2.9%)
APOE Â4 allele frequencyb
No Â4 86.9% 82.6% 87.1% 60.3%
Â4 present 13.1% 17.4% 12.9% 39.7%
a For the entire group: ¯ 2 = 63.2, d.f. = 12, p ! 0.0001.
b ¯2 test between healthy controls, EOD, and LOD patients: ¯ 2 = 2.5, d.f. = 2, p = 0.29.
¯2 test between healthy controls and LOD patients: ¯ 2 = 0.02, d.f. = 1, p 1 0.5.
¯2 test between EOD and LOD patients: ¯ 2 = 0.5, d.f. = 1, p = 0.5.
All comparisons were corrected for multiple testing.
comparison: (a) the positive association between APOE
genotype and depression was based on an insufficient
number of depressed patients (12 early-onset depressed
and 30 late-onset depressed patients) [5], (b) the defini-
tion of the age at onset for late-life depression varies (i.e.
145, 60, or 65 years) [5, 10, 14], (c) some authors use the
term depressive illness after development of AD [8], and
(d) other authors define depressive episodes in elderly
patients as geriatric depression, even though they suffered
from recurrent depression which first appeared in their
30s [15].
These apparent controversies led us to examine the
association between depression and the genetic polymor-
phism of APOE in a large sample of depressed patients,
AD patients, and healthy controls following clear defini-
tions for late-life depression. In order to exclude the possi-
bility that the arbitrary subdivision of depression into an
early-onset and a late-onset form confounded our analy-
sis, we further examined the cumulative incidence of
depression depending on the age at onset of the first epi-
sode using survival analysis.
Material and Methods
German AD patients (n = 102) with a mean age of 74.4 B 10.3
years (range 51–101 years) were recruited from the out-patient mem-
ory disorders clinic of the Psychiatric Department of the University
of Bonn; there were 68 (66.7%) females. The diagnosis of probable
AD was performed by standard clinical evaluation according to
NINCDS-ADRDA criteria [16]. Medical and family history, general
medical and neurological examination, psychiatric interview, neu-
ropsychological testing, blood and CSF studies, and CT scans were
carried out to exclude other forms of dementia. Depressed patients
(n = 160) were consecutively recruited in the Departement of Psy-
chiatry, University of Bonn. The mean age was 68.0 B 7.7 years
(range:50–88 years). There were 105 female patients (65.6%). Non-
demented, depressed patients underwent the same clinical evalua-
tion as the AD group. The diagnosis of depression was made by 2
independent experienced psychiatrists. Patients with LOD (n = 31)
were subjects 60 years of age or above at the first occurrence of a
depressive episode (mean age: 70.2 B 6.6 years, range: 61–86 years).
Patients with other psychiatric disorders (e.g. schizophrenia, schi-
zoaffective disorder, bipolar disorder) were not included. With the
support of the local Census Bureau and the regional Board of Data
Protection (Nordrhein-Westfalen, Germany) a stratified random
sample of subjects aged over 50 years was selected from the elderly
general population. The control group comprised 191 healthy sub-
jects (92 males, 99 females) with a mean age of 70.6 B 11.4 years
(range 50–100 years). CT scans and liquor studies were not per-
formed in the healthy subjects from the general population. In this
group, exclusion of psychiatric disorders and dementia was made
after an extensive psychiatric interview and neuropsychological test-
ing. All patients and control subjects gave informed consent to partic-
ipate in the study.
Leukocyte DNA was isolated following standard protocols.
APOE genotyping was performed as described before [17]. APOE
genotypes included Â2/Â3, Â2/Â4, Â3/Â3, Â3/Â4, and Â4/Â4. The geno-
type Â2/Â2 was not observed. Genotyping was performed blind to
clinical diagnosis. Frequencies were compared with the ¯2 test. Sur-
vival analysis was performed using the Kaplan-Meier method and
the log rank statistics.
Results
Table 1 presents the distribution of the APOE geno-
types and the frequency of the APOE Â4 allele in healthy
controls, patients with early-onset depression (EOD), pa-
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Fig. 1. Cumulative incidence of depression
in non-demented, depressed patients with
no (–––) or those with at least one copy
(––––) of the APOE Â4 allele.
tients with LOD and AD patients. The significant overre-
presentation of the Â3/Â4 genotype and the Â4/Â4 genotype
in AD patients led to a very high ¯ 2 value when the entire
group was tested (¯2 = 63.2, d.f. = 12, p ! 0.0001). How-
ever, comparison of the APOE Â4 allele frequency in
healthy controls, EOD patients, and LOD patients re-
vealed no significant difference between these groups
(¯2 = 2.5, d.f. = 2, p = 0.29). This applied also to pairwise
comparisons between EOD and LOD patients (¯2 = 0.5,
d.f. = 1, p = 0.5) and between healthy controls and LOD
patients (¯2 = 0.02, d.f. = 1, p 1 0.5).
Figure 1 shows the cumulative incidence of depression
depending on the age at onset for non-demented, de-
pressed patients with no or those with at least one copy of
the APOE Â4 allele. There was no significant difference
between the corresponding Kaplan-Meier curves (log rank
statistics = 0.4, d.f. = 1, p = 0.8).
Discussion
The assumption that depressive illness and AD are dis-
tinct syndromes which may share common biological
components [18] has recently found support by the find-
ing that depressed AD patients show increased familial
liability for depression that is independent of any familial
liability for dementia [19]. Despite the absence of corre-
sponding histopathological or experimental data, the ob-
served increased frequency of the APOE Â3/Â4 genotype
in non-demented, late-onset depressed patients [5] pro-
vided a missing link in the pathogenesis of AD and
depression, although this observation was challenged by
subsequent studies in elderly depressed patients [9, 10,
14, 15]. However, comparison of these studies is ham-
pered by the fact that different definitions for the diagno-
sis of late-life depression were used, and that the number
of depressed subjects was insufficient in many studies.
In the present study we used a large sample of healthy
controls, depressed patients, and AD patients, and de-
fined late-life depression in accordance with most authors
[20–22]. We could not replicate the finding by Krishnan
et al. [5], since there was no difference in the distribution
of the APOE genotype in healthy controls and patients
with LOD and EOD. The APOE allele frequencies were in
almost perfect agreement with other studies [10]. More-
over, the performed survival analysis showed that the
APOE Â4 allele has no influence on the age at onset of
depression. The hypothesis of depression sharing some
common pathophysiologic features with AD is not ex-
cluded by this data, however, it seems very unlikely that
the APOE genotype will elucidate the assumed common
mechanisms.
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